6BU0 logo

Burning Rock Biotech DB:6BU0 Stock Report

Last Price

€1.41

Market Cap

€65.4m

7D

0%

1Y

-79.0%

Updated

17 Dec, 2024

Data

Company Financials

Burning Rock Biotech Limited

DB:6BU0 Stock Report

Market Cap: €65.4m

6BU0 Stock Overview

Primarily develops and sells cancer therapy selection tests in the People's Republic of China. More details

6BU0 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Burning Rock Biotech Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Burning Rock Biotech
Historical stock prices
Current Share PriceUS$1.41
52 Week HighUS$8.70
52 Week LowUS$1.41
Beta0.60
1 Month Change0%
3 Month Change-15.06%
1 Year Change-78.96%
3 Year Changen/a
5 Year Changen/a
Change since IPO-94.00%

Recent News & Updates

Recent updates

Shareholder Returns

6BU0DE BiotechsDE Market
7D0%-2.6%-2.0%
1Y-79.0%-13.2%6.8%

Return vs Industry: 6BU0 underperformed the German Biotechs industry which returned -11.8% over the past year.

Return vs Market: 6BU0 underperformed the German Market which returned 10% over the past year.

Price Volatility

Is 6BU0's price volatile compared to industry and market?
6BU0 volatility
6BU0 Average Weekly Movementn/a
Biotechs Industry Average Movement6.9%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.4%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 6BU0's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine 6BU0's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2014786Yusheng Hanwww.brbiotech.com

Burning Rock Biotech Limited primarily develops and sells cancer therapy selection tests in the People's Republic of China. It operates through three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.

Burning Rock Biotech Limited Fundamentals Summary

How do Burning Rock Biotech's earnings and revenue compare to its market cap?
6BU0 fundamental statistics
Market cap€65.41m
Earnings (TTM)-€55.86m
Revenue (TTM)€66.74m

1.0x

P/S Ratio

-1.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6BU0 income statement (TTM)
RevenueCN¥510.89m
Cost of RevenueCN¥159.79m
Gross ProfitCN¥351.09m
Other ExpensesCN¥778.64m
Earnings-CN¥427.54m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-41.68
Gross Margin68.72%
Net Profit Margin-83.69%
Debt/Equity Ratio0%

How did 6BU0 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/17 16:12
End of Day Share Price 2024/09/19 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Burning Rock Biotech Limited is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bo LiBofA Global Research
null nullChina International Capital Corporation Limited
Ziyu HeChina International Capital Corporation Limited